AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid

Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Figure 1 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 2 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 3 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 5 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 6 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Table 1 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table 2 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table 3 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2